Phase I Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 18 Years or Above

A Randomized, Blinded and Placebo-Control Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 18 Years or Above

The primary objective of this study is to evaluate the tolerability, reactogenicity and safety of a single injection of three dose levels of ABO1105 in adults aged 18 years or above.

Study Overview

• Status: Active, not recruiting
• Conditions: Respiratory Syncytial Virus
• Intervention / Treatment: Drug: Placebo; Biological: ABO1105

• Study Type: Interventional
• Enrollment (Actual): 96
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Baise
    • Baise City, Baise, China
      • Baise Center For Disease Control & Prevention

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Voluntarily sign the Informed Consent Form (ICF) approved by the Ethics Committee and agree to participate in the trial before undergoing any trial procedures.
2. Healthy adults ≥18 years of age, participants with underlying diseases that are stably controlled may be accepted.
3. Willing to and physically able to communicate with the investigators, understand and comply with protocol required follow-up, simple self-observation and recording using the Diary Card.
4. Male participants (and their female partners) and female participants of childbearing potential agree to continue effective contraception through 3 months following vaccination.

Exclusion Criteria:

1. Presence of one or more respiratory symptoms within 7 days prior to vaccination, lasting for at least 24 hours.
2. Acute illness or fever on the day of vaccination or within 3 days prior to vaccination, or use of anti-inflammatory, anti-allergy, antibiotic, or antiviral medications due to physical discomfort.
3. Laboratory-confirmed history of RSV infection within the past 12 months, or previous vaccination with a respiratory syncytial virus vaccine.

4. Clinically significant abnormal vital signs, including but not limited to:

   • Resting pulse rate <50 beats per minute or >100 beats per minute
   • Systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg for participants aged 18-59, or systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥90 mmHg for participants aged ≥60
   • Body mass index (BMI) ≤18 kg/m² or ≥30 kg/m²
5. .Clinically significant abnormalities of laboratory indicators or 12-lead ECG during the screening period.
6. Female participants known to be pregnant or breastfeeding, or positive pregnancy test for women of childbearing potential.
7. History of allergy to the investigational products or its excipients, or severe allergic reactions to other vaccines, foods, or medications.
8. Use or planned use of any vaccine other than the investigational products through 30 days prior to and 30 days after vaccination in this trial.
9. Current participation in another clinical trial within 30 days prior to vaccination or planned participation before the end of this trial.
10. Clinician-diagnosed coagulation abnormalities.
11. Known medical history or diagnosis confirming the subject has a condition affecting immune system function.
12. History of myocarditis, pericarditis, or idiopathic cardiomyopathy, or presence of any condition that may increase the risk of myocarditis or pericarditis.
13. Severe or uncontrolled respiratory, cardiovascular, neurological, hematological, lymphatic, hepatic, renal, metabolic, or skeletal diseases; known severe congenital malformations; developmental disorders; or clinically diagnosed severe chronic conditions that may affect trial outcomes.
14. Current infectious period of any communicable disease, acute infection, or acute phase of chronic infection, or ongoing anti-tuberculosis treatment; or prior positive test for hepatitis B surface antigen, hepatitis C virus antibody, or Treponema pallidum antibody.
15. Past or current diagnosis of neurological or psychiatric disorders, or family history of neurological/psychiatric disorders; or other neurological conditions deemed unsuitable for trial participation by the investigator.
16. Long-term use of immunosuppressants or immunomodulators within 6 months prior to vaccination, excluding topical medications. Topical medications should not exceed recommended doses or induce systemic exposure.
17. Treatment with immunoglobulins and/or blood products or blood donation through 3 months prior to and 3 months after vaccination in this trial.
18. Suspected or known alcohol dependence or drug abuse, which may affect safety assessment or trial compliance.
19. Planned long-term or permanent relocation away from the trial site area before trial completion.
20. Investigators, sponsors, and contract research organization (CRO) staff directly involved in the trial.
21. Other circumstances deemed unsuitable for trial participation by the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Cohort 1: Dose level A in adults aged 18 years or above; Single injection of Dose level A of ABO1105	Drug: Placebo; 0.9% sodium chloride (normal saline) injection; Biological: ABO1105; Formulation for injection
Other: Cohort 2: Dose level B in adults aged 18 years or above; Single injection of Dose level B of ABO1105	Drug: Placebo; 0.9% sodium chloride (normal saline) injection; Biological: ABO1105; Formulation for injection
Other: Cohort 3: Dose level C in adults aged 18 years or above; Single injection of Dose level C of ABO1105	Drug: Placebo; 0.9% sodium chloride (normal saline) injection; Biological: ABO1105; Formulation for injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Incidence of solicited AEs and ARs after a single dose	up to Day 14
Incidence of unsolicited AEs and ARs after a single dose	up to Day 30

Collaborators and Investigators

• Sponsor: Suzhou Abogen Biosciences Co., Ltd.
• Collaborators: Abogen Biosciences (Shanghai) Co., Ltd

Study record dates

Study Major Dates

• Study Start (Actual): May 27, 2025
• Primary Completion (Actual): September 4, 2025
• Study Completion (Estimated): June 27, 2026

Study Registration Dates

• First Submitted: December 4, 2025
• First Submitted That Met QC Criteria: December 4, 2025
• First Posted (Actual): December 17, 2025

Study Record Updates

• Last Update Posted (Actual): December 17, 2025
• Last Update Submitted That Met QC Criteria: December 4, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Other Study ID Numbers: ABO1105-101

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No